ライフサイエンスコーパス: infective endocarditis

1 with Streptococcus mutans and virulence for infective endocarditis.

2 sociated permease A [BepA]), as important in infective endocarditis.

3 attack, recurrent acute rheumatic fever, and infective endocarditis.

4 of the many bacterial species implicated in infective endocarditis.

5 h to advance the understanding of left-sided infective endocarditis.

6 foci of infection, and no clinical signs of infective endocarditis.

7 colonizes teeth and is an important cause of infective endocarditis.

8 r ~5.7 x enhancement in imaging of S. aureus infective endocarditis.

9 eptococcus sanguinis is a causative agent of infective endocarditis.

10 iction of the embolism risk in patients with infective endocarditis.

11 tor of embolic events (EEs) in patients with infective endocarditis.

12 igens enhanced disease severity as tested by infective endocarditis.

13 ignificant negative impact on the outcome of infective endocarditis.

14 olic risk (ER) at admission of patients with infective endocarditis.

15 the appropriate management and treatment of infective endocarditis.

16 uggests novel therapeutic options to prevent infective endocarditis.

17 gh-level aminoglycoside-resistant E faecalis infective endocarditis.

18 rted in the literature, mainly as a cause of infective endocarditis.

19 total cohort of 2760 patients with definite infective endocarditis.

20 ely central mechanism in the pathogenesis of infective endocarditis.

21 population, and a leading causative agent of infective endocarditis.

22 lure (HF) is the most common complication of infective endocarditis.

23 is an important step in the pathogenesis of infective endocarditis.

24 studied 56 patients with definite left-sided infective endocarditis.

25 of the life-threatening endovascular disease infective endocarditis.

26 eport the first case of KPLA associated with infective endocarditis.

27 ent of human dental caries and, at times, of infective endocarditis.

28 ptococcus sanguinis is an important cause of infective endocarditis.

29 platelets contributes to the pathogenesis of infective endocarditis.

30 n was essential for the development of early infective endocarditis.

31 plex decision about surgical intervention in infective endocarditis.

32 s was on bacterial species reported to cause infective endocarditis.

33 minant of the bacterium in the initiation of infective endocarditis.

34 ns group streptococcal species implicated in infective endocarditis.

35 temcomitans is implicated in the etiology of infective endocarditis.

36 iagnostic procedures really are the cause of infective endocarditis.

37 a greater threat for individuals at risk for infective endocarditis.

38 odontitis and extraoral infections including infective endocarditis.

39 s and subsequent management of patients with infective endocarditis.

40 ith the highest risk of adverse outcome from infective endocarditis.

41 nth mortality among patients with left-sided infective endocarditis.

42 t from national and international experts on infective endocarditis.

43 alizations (65+/-17 years, 51% females) with infective endocarditis.

44 present in 556 (20.1%) of 2670 patients with infective endocarditis.

45 ive and prospective studies of prevention of infective endocarditis.

46 an increased lifetime risk of acquisition of infective endocarditis.

47 important for cariogenesis, bacteremia, and infective endocarditis.

48 diography in the diagnosis and management of infective endocarditis.

49 may be an important virulence determinant of infective endocarditis.

50 ains were observed by using the rat model of infective endocarditis.

51 s can also cause systemic disease, including infective endocarditis.

52 herapy in a therapeutic model of established infective endocarditis.

53 tulated central event in the pathogenesis of infective endocarditis.

54 43% of hospitalizations for IDRIs involved infective endocarditis.

55 n of causal agents in blood culture-negative infective endocarditis.

56 y play a central role in the pathogenesis of infective endocarditis.

57 to assist in the diagnosis and management of infective endocarditis.

58 rhusiopathiae septic arthritis and possible infective endocarditis.

59 volutionized the diagnosis and management of infective endocarditis.

60 this bacterium may cause the serious illness infective endocarditis.

61 ntibiotic prophylaxis guidelines on incident infective endocarditis.

62 nism involved in neurologic complications of infective endocarditis.

63 ith C. burnetii can cause a life-threatening infective endocarditis.

64 Infective endocarditis.

65 re complications of Streptococcus agalactiae infective endocarditis.

66 coccus oralis is a leading cause of subacute infective endocarditis.

67 endocarditis and in-hospital mortality after infective endocarditis.

68 icantly associated with an increased risk of infective endocarditis.

69 ary tract infections (UTIs), bacteremia, and infective endocarditis.

70 ac deaths 21.3%, reoperation on the MV 4.6%, infective endocarditis 1.1%, thromboembolism 10.3%, and

71 (3.49/1000 patient-years), and 20 (0.7%) had infective endocarditis (3.65/1000 patient-years).

72 h infective endocarditis, 66 patients (54%); infective endocarditis, 46 patients (38%; 15 with bicusp

73 e: congenital malformation unassociated with infective endocarditis, 66 patients (54%); infective end

74 Streptococcus sanguinisis a leading cause of infective endocarditis, a life-threatening infection of

75 ponses to vancomycin therapy in experimental infective endocarditis, a prototypical biofilm model.

76 It is also one of the most common agents of infective endocarditis, a serious endovascular infection

77 nal Registry included patients with definite infective endocarditis after TAVR from 47 centers from E

78 Infective endocarditis after TAVR most frequently occurs

79 ssociated with higher risk of progressing to infective endocarditis after TAVR was younger age (78.9

80 es, types of microorganisms, and outcomes of infective endocarditis after TAVR.

81 acteristics and outcomes of patients who had infective endocarditis after undergoing transcatheter ao

82 f Diseases, ninth revision, codes indicating infective endocarditis among admissions of patients <21

83 i are integral events in the pathogenesis of infective endocarditis and atherosclerosis.

84 cause hospital-acquired infections, such as infective endocarditis and catheter-associated urinary t

85 ycin and imipenem as rescue therapy for MRSA infective endocarditis and complicated bacteremia.

86 anguinis class Ib RNR in an animal model for infective endocarditis and establishing whether the mang

87 Streptococcus sanguinis is a cause of infective endocarditis and has been shown to require a m

88 Infective endocarditis and in-hospital mortality after i

89 er aortic valve replacement for incidence of infective endocarditis and infective endocarditis for in

90 Of 4075 patients with infective endocarditis and known HF status enrolled, 135

91 associated with systemic diseases, including infective endocarditis and neutropenic bacteremia.

92 sent article reviews the challenges posed by infective endocarditis and outlines current and future s

93 by viridans group streptococci can result in infective endocarditis and possibly atherosclerosis; how

94 the incidence, microbiology, and outcomes of infective endocarditis and the effect of changes in nati

95 ificant for both individuals at high risk of infective endocarditis and those at lower risk.

96 challenge in a prophylactic model of rabbit infective endocarditis, and enhance the efficacy of vanc

97 al effect on the interpretation of trends in infective endocarditis, and recent studies have proposed

98 with or without AIDS, the viral hepatitides, infective endocarditis, and skin and soft-tissue infecti

99 s has become an increasingly common cause of infective endocarditis, and the microbiology of nosocomi

100 ylaxis recommendations for the prevention of infective endocarditis are based in part on studies of b

101 in diagnosis, microbiology, and treatment of infective endocarditis are described, and case definitio

102 ntimicrobial guidelines for the treatment of infective endocarditis are readily available, including

103 The challenges posed by infective endocarditis are significant.

104 We compared the incidence of infective endocarditis before and after the introduction

105 The risk for embolism during infective endocarditis can be quantified at admission us

106 Infective endocarditis caused by non-HACEK (species othe

107 eremia and associated sternal osteomyelitis, infective endocarditis) caused by Staphylococcus aureus.

108 In this cohort of patients with infective endocarditis complicated by HF, severity of HF

109 Infective endocarditis continues to pose major challenge

110 Pathogenic mechanisms in infective endocarditis, disseminated intravascular coagu

111 by doxorubicin plus cyclophosphamide group), infective endocarditis (docetaxel plus bevacizumab follo

112 Drug use-associated infective endocarditis (DUA-IE) is increasing as a resul

113 curately capture data on drug use-associated infective endocarditis (DUA-IE).

114 Infective endocarditis due to vancomycin-resistant (VR)

115 binations for treating Enterococcus faecalis infective endocarditis (EFIE).

116 ensis, an opportunistic pathogen that causes infective endocarditis, encodes an Isd system.

117 ion of interest was all hospitalizations for infective endocarditis, epidural abscess, septic arthrit

118 ted hospitalizations for serious infections (infective endocarditis, epidural abscess, septic arthrit

119 (95% CI, 10.4%-19.2%) of patients during the infective endocarditis episode.

120 antibiotic prophylaxis for the prevention of infective endocarditis fell substantially after introduc

121 for incidence of infective endocarditis and infective endocarditis for in-hospital mortality.

122 age approach, all patients hospitalized with infective endocarditis from 1990 to 2014 were identified

123 educing gentamicin treatment in enterococcal infective endocarditis from 4 to 6 weeks to only 2 weeks

124 ts with definite native- or prosthetic-valve infective endocarditis from 61 centers in 28 countries b

125 t of 1345 consecutive episodes of left-sided infective endocarditis from 8 centers in Spain.

126 ics for patients with a primary diagnosis of infective endocarditis from Jan 1, 2000, to March 31, 20

127 revealed higher microglial activation in the infective endocarditis group (n = 11/23, 48%), when comp

128 In the infective endocarditis group, MRI revealed at least one

129 In the infective endocarditis group, neuropathology revealed br

130 group were similar to those observed in the infective endocarditis group.

131 The epidemiology of infective endocarditis has become more complex with toda

132 The diagnosis of infective endocarditis has been notoriously difficult.

133 procedures in patients at risk of developing infective endocarditis has historically been the focus o

134 ve fallen substantially and the incidence of infective endocarditis has increased significantly in En

135 The role of valve surgery in left-sided infective endocarditis has not been evaluated in randomi

136 ophylaxis guidelines, the crude incidence of infective endocarditis has remained stable.

137 Acute brain embolization (ABE) in left-sided infective endocarditis has significant implications for

138 Prophylaxis and treatment guidelines for infective endocarditis have changed substantially over t

139 - and sex-adjusted incidence and outcomes of infective endocarditis hospitalizations.

140 The clinical variability and complexity in infective endocarditis, however, dictate that these reco

141 Injection drug use-associated infective endocarditis (IDU-IE) is rising and valve surg

142 ong those with injection drug use-associated infective endocarditis (IDU-IE), against medical advice

143 atus, and dental procedures in patients with infective endocarditis (IE) according to whether the IE-

144 e incidence, clinical course, and outcome of infective endocarditis (IE) after TPV implant.

145 characteristics, management, and outcomes of infective endocarditis (IE) after transcatheter aortic v

146 y virus (HIV) infection and other factors on infective endocarditis (IE) among injection drug users (

147 to identify patients with increased risk of infective endocarditis (IE) among patients with Enteroco

148 ta sources and national burden estimates for infective endocarditis (IE) and skin and soft-tissue inf

149 e Staphylococcus aureus (MSSA) isolates from infective endocarditis (IE) and soft tissue infections (

150 ity to echocardiography in the evaluation of infective endocarditis (IE) and surgical planning.

151 Data on early determinants of outcome in infective endocarditis (IE) are limited.

152 Use of surgery for the treatment of infective endocarditis (IE) as related to surgical indic

153 ography plays a key role in the diagnosis of infective endocarditis (IE) but can be inconclusive in p

154 antibiotic prophylaxis for the prevention of infective endocarditis (IE) for only the highest-risk pa

155 of Cardiology and American Heart Association infective endocarditis (IE) guideline update, antibiotic

156 Rising rates of hospitalization for infective endocarditis (IE) have been increasingly tied

157 comes in people who inject drugs (PWID) with infective endocarditis (IE) have often been retrospectiv

158 comes in people who inject drugs (PWID) with infective endocarditis (IE) have often been retrospectiv

159 art Association guidelines for prevention of infective endocarditis (IE) in 2007 reduced the groups o

160 l database of all residents hospitalized for infective endocarditis (IE) in an acute care hospital fr

161 03/31/2017 of all residents hospitalized for infective endocarditis (IE) in an acute care hospital.

162 population-based epidemiological changes in infective endocarditis (IE) in Europe.

163 ed as a useful diagnostic tool for suspected infective endocarditis (IE) in patients with prosthetic

164 The diagnosis of infective endocarditis (IE) in prosthetic valves and int

165 of Diseases, 9thRevision diagnosis codes for infective endocarditis (IE) in the National Inpatient Sa

166 his study was to evaluate temporal trends in infective endocarditis (IE) incidence and clinical chara

167 Infective endocarditis (IE) is a complex disease with ca

168 Infective endocarditis (IE) is a rare disease with poor

169 Infective endocarditis (IE) is a serious complication of

170 Early diagnosis of infective endocarditis (IE) is based on the yielding of

171 or and treating the portal of entry (POE) of infective endocarditis (IE) is important, but published

172 es of resected heart valves of patients with infective endocarditis (IE) is influenced by pre-operati

173 Gram-negative bacilli causing infective endocarditis (IE) is rare, even in intravenous

174 Infective endocarditis (IE) is the most feared complicat

175 a expression in vitro and in an experimental infective endocarditis (IE) model using flow cytometry.

176 ctin binding in vitro and in an experimental infective endocarditis (IE) model using parental strains

177 Infective endocarditis (IE) mostly occurs after spontane

178 Infective endocarditis (IE) often requires surgical inte

179 No data exist about the characteristics of infective endocarditis (IE) post-transcatheter aortic va

180 Association published updated guidelines for infective endocarditis (IE) prevention in 2007 that mark

181 Background Infective endocarditis (IE) remains a difficult to diagn

182 he timing of cardiac surgery after stroke in infective endocarditis (IE) remains controversial.

183 rvational studies showed that the profile of infective endocarditis (IE) significantly changed over t

184 ct of vancomycin MIC on left-sided S. aureus infective endocarditis (IE) treated with cloxacillin.

185 biotic prophylaxis (AP) for those at risk of infective endocarditis (IE) undergoing dental procedures

186 g, and the number of episodes complicated by infective endocarditis (IE) varies.

187 The diagnosis of infective endocarditis (IE) was established by using the

188 ET/CT) is commonly used for the diagnosis of infective endocarditis (IE), but its prognostic value re

189 staphylococci (CNS) are important causes of infective endocarditis (IE), but their microbiological p

190 e incidence of bacterial infections, such as infective endocarditis (IE), have been reported in conju

191 c valve abnormalities have increased risk of infective endocarditis (IE), it is unknown whether these

192 l cavity, is an important etiologic agent of infective endocarditis (IE), particularly in people with

193 ment in surgical mortality for patients with infective endocarditis (IE), presumably because of impro

194 In the management of infective endocarditis (IE), the presence of extracardia

195 from methicillin-resistant S. aureus (MRSA) infective endocarditis (IE), we characterized patients w

196 significant increases in infections such as infective endocarditis (IE), which is tied to injection

197 Streptococci frequently cause infective endocarditis (IE), yet the prevalence of IE in

198 tal role in the evaluation and management of infective endocarditis (IE)-a condition with high morbid

199 Substantial infective endocarditis (IE)-related morbidity and mortal

200 chemic stroke (IS) during the acute phase of infective endocarditis (IE).

201 ncreased risk of deleterious sequelae due to infective endocarditis (IE).

202 ntibiotic prophylaxis in patients at risk of infective endocarditis (IE).

203 nse against endovascular infections, such as infective endocarditis (IE).

204 t (OPAT) has proven efficacious for treating infective endocarditis (IE).

205 faecalis is the third most frequent cause of infective endocarditis (IE).

206 of hemorrhagic stroke (HS) in patients with infective endocarditis (IE).

207 cement (SAVR) are considered at high risk of infective endocarditis (IE).

208 tal plaque and important agents of bacterial infective endocarditis (IE).

209 assess the characteristics of children with infective endocarditis in a large national sample.

210 tients presenting with definite diagnoses of infective endocarditis in a multicenter observational co

211 e are effects of gC1qR blockade on S. aureus infective endocarditis in addition to blocking gC1qR-med

212 eases of the skeletal system in children and infective endocarditis in children and adults.

213 um is also a cardiovascular pathogen causing infective endocarditis in children and adults.

214 Infective endocarditis in children is rare, and most rep

215 is versus no prophylaxis on the incidence of infective endocarditis in England.

216 , and is also implicated in causing subacute infective endocarditis in humans.

217 stic pathogen, as well as a leading cause of infective endocarditis in humans.

218 counts for a high percentage of all cases of infective endocarditis in many regions of the world.

219 of antibiotic prophylaxis for prevention of infective endocarditis in March, 2008.

220 cus is an increasing cause of bacteremia and infective endocarditis in the elderly.

221 fy trends in the incidence and etiologies of infective endocarditis in the United States.

222 e regarding procedure-related bacteremia and infective endocarditis, in vitro susceptibility data of

223 rting in March, 2008, the number of cases of infective endocarditis increased significantly above the

224 development of large caseous lesions, and in infective endocarditis, increases the size of pathognomo

225 Infective endocarditis is a complex disease, and patient

226 Infective endocarditis is a complex disease, with many h

227 Infective endocarditis is a life-threatening disease wit

228 Infective endocarditis is a potentially lethal disease t

229 Infective endocarditis is a typical biofilm-associated i

230 mon cause of nosocomial infections, of which infective endocarditis is associated with substantial mo

231 important interaction in the pathogenesis of infective endocarditis is attachment of the organisms to

232 carditis, and the microbiology of nosocomial infective endocarditis is changing.

233 Infective endocarditis is defined by a focus of infectio

234 ival for people who inject drugs (PWID) with infective endocarditis is good, long-term survival is po

235 Infective endocarditis is life-threatening; identificati

236 udy suggest that valve surgery in left-sided infective endocarditis is not associated with a survival

237 Infective endocarditis is one of the most common clinica

238 Biofilms on native heart valves (infective endocarditis) is a life-threatening disease as

239 Similar structures were observed on all infective endocarditis isolates examined, suggesting tha

240 nagement-based approach for the treatment of infective endocarditis, leading to a strong reduction of

241 taphylococcus aureus left-sided native valve infective endocarditis (LNVIE) has higher complication a

242 tissues during cardiac surgery of left-sided infective endocarditis (LSIE) helps to guide antibiotic

243 Infective endocarditis may affect patients after transca

244 Infective endocarditis may require valve surgery, but su

245 t only an extremely small number of cases of infective endocarditis might be prevented by antibiotic

246 n of empA also resulted in attenuation in an infective endocarditis model (P = 0.0088).

247 ore resistant to vancomycin treatment in the infective endocarditis model than a RB comparator strain

248 Neurologic lesions observed in the infective endocarditis model were compared with three ot

249 Moreover, with the use of the rabbit infective endocarditis model, we demonstrate that the di

250 th their respective parental strains, in the infective endocarditis model.

251 athogenesis of Enterococcus faecium in a rat infective endocarditis model.

252 ry genes in vivo was carried out using a rat infective endocarditis model.

253 ibute to USA300 JE2 pathogenesis using a rat infective endocarditis model.

254 pose the highest risk for bad outcome should infective endocarditis occur and only for dental procedu

255 A total of 250 cases of infective endocarditis occurred in 20006 patients after

256 Infective endocarditis occurs worldwide, and is defined

257 Patients with infective endocarditis on the left side of the heart are

258 No infective endocarditis or aortic dissection was found.

259 ults in serious secondary infections such as infective endocarditis, osteomyelitis, and septic arthri

260 se of bacteraemia, which frequently leads to infective endocarditis, osteomyelitis, septic arthritis

261 of diagnosis, microbiology, and treatment of infective endocarditis, particularly as they are influen

262 ocarditis has historically been the focus of infective endocarditis prevention.

263 (2) Infective endocarditis prophylaxis for dental procedures

264 ges are intended to define more clearly when infective endocarditis prophylaxis is or is not recommen

265 ng the following search terms: endocarditis, infective endocarditis, prophylaxis, prevention, antibio

266 Staphylococcus aureus (SA) prosthetic valve infective endocarditis (PVIE) is unresolved.

267 to define the cerebral lesion spectrum in an infective endocarditis rat model.

268 This original model of infective endocarditis recapitulates the neurologic lesi

269 Despite improvements in management, infective endocarditis remains associated with high mort

270 of the most common microorganisms that cause infective endocarditis, results of prophylactic studies

271 surgery on outcomes of Staphylococcus aureus infective endocarditis (SAIE) remains controversial.

272 n vivo during infections in rabbit models of infective endocarditis, sepsis, and pneumonia.

273 auses life-threatening infections, including infective endocarditis, sepsis, and pneumonia.

274 All patients with suspected infective endocarditis should undergo transthoracic echo

275 To identify virulence factors for infective endocarditis, signature-tagged mutagenesis (ST

276 antibiotic prophylaxis and the incidence of infective endocarditis since the introduction of these g

277 During pathogenesis of infective endocarditis, Staphylococcus aureus adherence

278 red proteins may play a role in S. sanguinis infective endocarditis, strategies designed to interfere

279 reveal that the oral colonizer and cause of infective endocarditis Streptococcus oralis subsp. denti

280 ill develop serious complications, including infective endocarditis, sudden cardiac death, and severe

281 bstantial number of patients with left-sided infective endocarditis, suggesting that the incidence of

282 eart Association (AHA) for the prevention of infective endocarditis that were last published in 1997.

283 neurological complications in patients with infective endocarditis, the risk factors for their devel

284 nuing shift in the epidemiology of pediatric infective endocarditis toward a higher proportion of chi

285 comes in patients with Enterococcus faecalis infective endocarditis treated in the years before and a

286 nical characteristics of HF in patients with infective endocarditis, use of surgical therapy, and the

287 as an index test, (b) data were provided as infective endocarditis valvular complications (classifie

288 The annualized incidence of infective endocarditis was 1.6% in the Melody group and

289 Median time from TAVR to infective endocarditis was 5.3 months (interquartile ran

290 ement of each cell wall-anchored protein for infective endocarditis was assessed in the rabbit model.

291 Infective endocarditis was classified into early (peri-p

292 urvival free of valve replacement because of infective endocarditis was comparable between both group

293 Health care-associated infective endocarditis was present in 52.8% (95% CI, 46.

294 Association guidelines for the prevention of infective endocarditis was recently published in their j

295 This increase in the incidence of infective endocarditis was significant for both individu

296 State, the overall standardized incidence of infective endocarditis was stable from 1998 through 2013

297 of aminoglycosides, the Danish guidelines on infective endocarditis were changed in January 2007, red

298 of 546 consecutive patients with left-sided infective endocarditis were included.

299 ar survival, freedom of reinterventions, and infective endocarditis with or without the need of repla

300 eir expertise in prevention and treatment of infective endocarditis, with liaison members representin